share_log

Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $14

Benzinga ·  May 7 13:37

Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $15 to $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment